These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26582645)

  • 21. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
    Patel KP; Ravandi F; Ma D; Paladugu A; Barkoh BA; Medeiros LJ; Luthra R
    Am J Clin Pathol; 2011 Jan; 135(1):35-45. PubMed ID: 21173122
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Molenaar RJ; Radivoyevitch T; Nagata Y; Khurshed M; Przychodzen B; Makishima H; Xu M; Bleeker FE; Wilmink JW; Carraway HE; Mukherjee S; Sekeres MA; van Noorden CJF; Maciejewski JP
    Clin Cancer Res; 2018 Apr; 24(7):1705-1715. PubMed ID: 29339439
    [No Abstract]   [Full Text] [Related]  

  • 23. Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
    Xu Q; Li Y; Lv N; Jing Y; Xu Y; Li Y; Li W; Yao Z; Chen X; Huang S; Wang L; Li Y; Yu L
    Clin Cancer Res; 2017 Aug; 23(15):4511-4522. PubMed ID: 28246275
    [No Abstract]   [Full Text] [Related]  

  • 24. IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis.
    Kattih B; Shirvani A; Klement P; Garrido AM; Gabdoulline R; Liebich A; Brandes M; Chaturvedi A; Seeger T; Thol F; Göhring G; Schlegelberger B; Geffers R; John D; Bavendiek U; Bauersachs J; Ganser A; Heineke J; Heuser M
    Leukemia; 2021 May; 35(5):1301-1316. PubMed ID: 32948843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
    Zhou KG; Jiang LJ; Shang Z; Wang J; Huang L; Zhou JF
    Leuk Lymphoma; 2012 Dec; 53(12):2423-9. PubMed ID: 22616558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
    Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated plasma 2-hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment.
    Wiseman DH; Small HF; Wilks DP; Waddell ID; Dennis MW; Ogilvie DJ; Somervaille TC
    Br J Haematol; 2014 Jul; 166(1):145-8. PubMed ID: 24606602
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
    Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.
    Salhotra A; Afkhami M; Yang D; Mokhtari S; Telatar M; Gu D; Pillai RK; Weisenburger DD; Murata-Collins J; Weigel D; Aoun P; Aldoss I; Al Malki MM; Khaled S; Mei M; Ali H; Aribi A; Budde E; Sandhu K; O'Donnell M; Snyder D; Pullarkat V; Forman SJ; Marcucci G; Nakamura R; Stein A
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e400-e405. PubMed ID: 31155409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation.
    Raveendran S; Sarojam S; Vijay S; Geetha AC; Sreedharan J; Narayanan G; Sreedharan H
    Asian Pac J Cancer Prev; 2015; 16(9):4095-101. PubMed ID: 25987093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.
    Middeke JM; Metzeler KH; Röllig C; Krämer M; Eckardt JN; Stasik S; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Brümmendorf TH; Naumann R; Steffen B; Einsele H; Schaich M; Burchert A; Neubauer A; Görlich D; Sauerland C; Schäfer-Eckart K; Schliemann C; Krause SW; Hänel M; Frickhofen N; Noppeney R; Kaiser U; Kaufmann M; Kunadt D; Wörmann B; Sockel K; von Bonin M; Herold T; Müller-Tidow C; Platzbecker U; Berdel WE; Serve H; Baldus CD; Ehninger G; Schetelig J; Hiddemann W; Bornhäuser M; Stölzel F; Thiede C
    Blood Adv; 2022 Mar; 6(5):1394-1405. PubMed ID: 34794176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of azacitidine in 93 patients with
    Willekens C; Rahme R; Duchmann M; Vidal V; Saada V; Broutin S; Delahousse J; Renneville A; Marceau A; Clappier E; Uzunov M; Rossignol J; Pascal L; Simon L; Micol JB; Pasquier F; Raffoux E; Preudhomme C; Quivoron C; Itzykson R; Penard-Lacronique V; Paci A; Fenaux P; Attar EC; Frattini M; Braun T; Ades L; De Botton S
    Leuk Lymphoma; 2021 Feb; 62(2):438-445. PubMed ID: 33043739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
    Schnittger S; Haferlach C; Ulke M; Alpermann T; Kern W; Haferlach T
    Blood; 2010 Dec; 116(25):5486-96. PubMed ID: 20805365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
    Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
    Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
    N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
    Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F;
    J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
    Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
    Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.
    Cairns RA; Mak TW
    Cancer Discov; 2013 Jul; 3(7):730-41. PubMed ID: 23796461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.